bruton tyrosine kinase inhibitors the present invention relates to a novel compound of formula i: formula i or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein: v1 is c or n, v2 is c (r2) or n, whereby if v1 is c then v2 is n, if v1 is c then v2 is ¿(r2), or if v1 is n then v2 is ¿(r2)； each n, k is independently 0.1； each r2, r11 is independently h, d, hal, cn, nr? r ??, c (o) nr? r ??, C1-6 alkoxy； R 3 is h, d, hydroxy, C 1-6 alkyl (o), C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkyl； R4 is h, hal, cn, conr 'r', hydroxy, C1-C6 alkyl, C1-C6 alkoxy； l is ch2, nh, ¿or chemical bond； r1 is selected from the group of fragments, comprising: fragment 1, fragment 2, fragment 3 each ¿1, ¿2, ¿3, ¿4 is independently ¿¿, n, ¿hal； each ¿5, ¿6, ¿7, ¿8, ¿9 is independently ¿, h or n； R5 is h, n, hal, conr? r ??, C1-C6 alkyl, unsubstituted or substituted by one or more halogens； each r? and r ?? is independently selected from the group, comprising h, C1-C6 alkyl, C1-C6 cycloalkyl, aryl； R 6 is selected from the group: each R 7, R 8, R 9, R 10 is independently vinyl, methylacetylenyl； hal is cl, br, i, f, which have bruton tyrosine kinase (btk) inhibitory properties, to pharmaceutical compositions containing such compounds, and their use as pharmaceuticals for the treatment of disease and disorder.inibidores de tirosina quinase de bruton a presente invenção refere-se a um novo composto da fórmula i: fórmula i ou sal, solvato ou estereoisômero farmaceuticamente aceitáveis deste, em que: v1 é c ou n, v2 é c(r2) ou n, por meio do qual se v1 for c então v2 é n, se v1 for c então v2 é ¿(r2), ou se v1 for n então v2 é ¿(r2)； cada n, k é independentemente 0, 1； cada r2, r11 é independentemente h, d, hal, cn, nr?r??, c(o)nr?r??, alcóxi c1-c6； r3 é h, d, hidróxi, alquila ¿(o)c1-c6, alquenila ¿(¿)c2-c6, alquinila ¿(¿)c2-c6, alquila c1-c6； r4 é h, hal, cn, conr?r??, hidróxi, alquila c1-c6, alcóxi c1-c6； l é ch2, nh, ¿ ou ligação química； r1 é selecionado do grupo dos fr
